Skip to content
Menu

Greenwich LifeSciences, Inc. GLSI

Full chart Compare
Set alert

Price alert · GLSI

All alert types
19.79 USD -0.79 (-3.84%)

Regular-session close

19.89 +0.10 +0.51%

After hours · Nov 19, 4:41 PM ET

19.39 Day range 20.97
7.78 52-week range 34.10
YTD
-5.81%
1 year
+143.42%

5D +4.39 (+28.51%)

1517.5020FriMonTueWedThu19.79
Market cap
290.48M
EPS (ttm)
-1.63
Shares out
13.14M
Forward P/E
-14.83
YTD return
-5.81%
1-year return
+143.42%
50-day average
13.57
200-day average
14.65
Volume
231.25K
Avg volume
155.38K
Open
20.54
Previous close
20.58
Day's range
19.39 – 20.97
52-week range
7.78 – 34.10
Beta
3.32
Price target
38.00 (+92.0%)

Key statistics

Enterprise value
171.41M
Price / book
23.30
Free cash flow
-3.15M
Total cash
7.22M
Return on equity
-123.67%
Short % of float
7.83%

Fundamental scorecard

4 of 25 checks passed on GLSI’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
GLSI Revenue — quarterly 0
GLSI Net income — quarterly -5.81M
GLSI EPS — quarterly -0.40

Earnings

GLSI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.21-0.20+0.01+4.76%
Aug 14, 2024Jun 1, 2024-0.20-0.200.000.00%
Aug 14, 2024Jun 1, 2024-0.20———
May 20, 2024Mar 1, 2024-0.20-0.19+0.01+5.00%
May 20, 2024Mar 1, 2024-0.20———
Apr 15, 2024Dec 1, 20230.00———

Upgrades / downgrades

GLSI analyst upgrades and downgrades
DateFirmActionFromTo
Aug 23, 2024HC Wainwright & Co.mainBuyBuy
May 22, 2024HC Wainwright & Co.reitBuyBuy
Feb 28, 2024HC Wainwright & Co.reitBuyBuy
Feb 20, 2024HC Wainwright & Co.mainBuyBuy
Apr 10, 2023HC Wainwright & Co.reit—Buy
Sep 1, 2021HC Wainwright & Co.init—Buy

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on GLSI — it syncs with the Stock Master app.

Insider holders

GLSI insider holders
InsiderRelationLatest transactionDateShares held
PATEL SNEHALChief Executive OfficerPurchaseSep 25, 20245,536,100
THOMPSON JAYE LOfficerPurchaseNov 20, 2024264,148

Institution ownership

GLSI institution ownership
Holder% heldSharesValueReported
Blackrock Inc.2.66%350,1444.26MSep 29, 2024
Vanguard Group Inc2.08%273,5253.33MSep 29, 2024
Geode Capital Management, LLC1.02%133,5501.62MSep 29, 2024
Credit Agricole S.A.0.66%87,0001.06MSep 29, 2024
Northern Trust Corporation0.57%74,500905.92KSep 29, 2024
State Street Corporation0.54%71,408868.32KSep 29, 2024

Fund ownership

GLSI fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.17%153,4591.87MSep 29, 2024
iShares Russell 2000 ETF1.08%141,6961.72MOct 30, 2024
Vanguard Extended Market Index Fund0.54%71,311867.14KSep 29, 2024
Fidelity Small Cap Index Fund0.47%61,696750.22KAug 30, 2024
iShares Russell 2000 Growth ETF0.39%50,661616.04KOct 30, 2024
Fidelity Extended Market Index Fund0.25%32,217391.76KOct 30, 2024